Riskpilot← Back to searchSign inGet full accessFENJA BIOSOLUTIONS AS
ASActiveOrg 930508357Karenslyst Allé 10, 0278 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20230 employeeswww.fenjabio.com
Revenue 2024
NOK 2K
EBITDA margin
-234.6%
Equity ratio
75.2%
Financial strength
Net profit 2024
NOK -6K
0 employees
| Revenue | NOK 2K | — |
| EBITDA | NOK -6K | — |
| Net profit | NOK -6K | — |
| Total assets | NOK 32K | +8% |
| Equity | NOK 24K | -19% |
| Employees | 0 | — |
Legal name
FENJA BIOSOLUTIONS AS
Org number
930508357
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
13. januar 2023
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Utvikling av teknologi for produksjon av alternative proteiner ved bruk av underutnyttede norske substrater som vekstmedium, spesielt fokusert på mycoproteiner for dyrefôr. Dette inkluderer forskning og utvikling, laboratorie- og pilotstudier, samt oppskalering til industriell produksjon. Virksomheten kan også drives gjennom deltakelse i eller i samarbeid med andre selskaper.
Address
Karenslyst Allé 10, 0278 Oslo
Website
www.fenjabio.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 |
|---|---|---|
| Revenue | 0 | 2 |
| Staff expenses | −0 | −0 |
| EBITDA | 0 | −6 |
| Depreciation & amort. | −0 | −0 |
| EBIT | 0 | −6 |
| Net financials | 0 | 0 |
| Profit before tax | 0 | −6 |
| Tax | −0 | −0 |
| Net profit | 0 | −6 |
| Item | 2023 | 2024 |
|---|---|---|
| Total assets | 30 | 32 |
| Equity | 30 | 24 |
| Long-term debt | 0 | 8 |
| Short-term debt | 0 | 0 |
| Total debt | 0 | 8 |
EBITDA margin
-234.6%
This company
15.8%
Market median
-1585% vs market
20232024
Equity ratio
75.2%
This company
38.2%
Market median
+97% vs market
20232024
Return on equity
-23.1%
This company
18.4%
Market median
-226% vs market
20232024
Net profit margin
-234.6%
This company
8.1%
Market median
-2996% vs market
20232024
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
20232024
Debt / equity
0.33×
This company
0.62×
Market median
+47% vs market
20232024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
IA Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2024 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2024 | — | — | |
| Chairman | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 23.3% | 23.3% | 2023 | |
| Individual | 23.3% | 23.3% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of FENJA BIOSOLUTIONS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Idar Alvestad | Chief Executive Officer | 0 companies |
| Jens Petter Broby | Chairman | 0 companies |
| Cathrine Nising Nedrum Lanne | Board of Directors | 0 companies |
| Thomas Steenbuch Tharaldsen | Chairman | 0 companies |
| Ida Louise Maj Sandin | Board of Directors | 0 companies |
| Kurt Ødegård | Chairman | 0 companies |
| Siri Moseng Reiersen | Chairman | 0 companies |